tradingkey.logo

GlucoTrack Inc

GCTK
查看詳細走勢圖
4.490USD
-0.010-0.22%
收盤 12/24, 13:00美東報價延遲15分鐘
4.04M總市值
虧損本益比TTM

GlucoTrack Inc

4.490
-0.010-0.22%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-0.22%

5天

-5.27%

1月

-6.46%

6月

-27.70%

今年開始到現在

-99.00%

1年

-98.55%

查看詳細走勢圖

TradingKey GlucoTrack Inc股票評分

單位: USD 更新時間: 2025-12-24

操作建議

GlucoTrack Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名242/404位。機構持股佔比很高,中期看,股價處於下降通道。近一個月,市場表現非常差,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

GlucoTrack Inc評分

相關信息

行業排名
242 / 404
全市場排名
497 / 4562
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 0 分析師
--
評級
--
目標均價
--
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

GlucoTrack Inc亮點

亮點風險
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
利潤高增長
公司淨利潤處於行業前列,最新年度總收入0.00美元
估值高估
公司最新PE估值-0.00,處於3年歷史高位
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉0.00股

GlucoTrack Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

GlucoTrack Inc簡介

Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
公司代碼GCTK
公司GlucoTrack Inc
CEOGoode (Paul V)
網址https://glucotrack.com/

常見問題

GlucoTrack Inc(GCTK)的當前股價是多少?

GlucoTrack Inc(GCTK)的當前股價是 4.490。

GlucoTrack Inc 的股票代碼是什麼?

GlucoTrack Inc的股票代碼是GCTK。

GlucoTrack Inc股票的52週最高點是多少?

GlucoTrack Inc股票的52週最高點是468.000。

GlucoTrack Inc股票的52週最低點是多少?

GlucoTrack Inc股票的52週最低點是4.220。

GlucoTrack Inc的市值是多少?

GlucoTrack Inc的市值是4.04M。

GlucoTrack Inc的淨利潤是多少?

GlucoTrack Inc的淨利潤為-22.60M。

現在GlucoTrack Inc(GCTK)的股票是買入、持有還是賣出?

根據分析師評級,GlucoTrack Inc(GCTK)的總體評級為--,目標價格為--。

GlucoTrack Inc(GCTK)股票的每股收益(EPS TTM)是多少

GlucoTrack Inc(GCTK)股票的每股收益(EPS TTM)是-1335.127。
KeyAI